Budesonide Formoterol Drug Combination + nebulisation of terbutaline
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma in Children
Conditions
Asthma in Children
Trial Timeline
Aug 23, 2021 โ Jun 23, 2023
NCT ID
NCT04705727About Budesonide Formoterol Drug Combination + nebulisation of terbutaline
Budesonide Formoterol Drug Combination + nebulisation of terbutaline is a phase 3 stage product being developed by AstraZeneca for Asthma in Children. The current trial status is terminated. This product is registered under clinical trial identifier NCT04705727. Target conditions include Asthma in Children.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04705727 | Phase 3 | Terminated |
Competing Products
20 competing products in Asthma in Children